NASDAQ:IMRX

Immuneering (IMRX) Stock Price, News & Analysis

$1.50
-0.13 (-7.98%)
(As of 04/24/2024 ET)
Today's Range
$1.47
$1.65
50-Day Range
$1.63
$6.76
52-Week Range
$1.47
$12.15
Volume
471,224 shs
Average Volume
566,940 shs
Market Capitalization
$43.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50

Immuneering MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
800.0% Upside
$13.50 Price Target
Short Interest
Bearish
13.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$3.05 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.89) to ($1.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.39 out of 5 stars

Medical Sector

234th out of 909 stocks

Pharmaceutical Preparations Industry

95th out of 423 stocks

IMRX stock logo

About Immuneering Stock (NASDAQ:IMRX)

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

IMRX Stock Price History

IMRX Stock News Headlines

3 Stocks Insiders Are Buying That Analysts Love
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Immuneering Co. (NASDAQ:IMRX) Short Interest Up 10.3% in March
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
Immuneering CEO acquires $55.3k in company stock
Immuneering Director Acquires 7.5% More Stock
See More Headlines
Receive IMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/01/2024
Today
4/24/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMRX
Fax
N/A
Employees
68
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.50
High Stock Price Target
$25.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+805.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-53,470,000.00
Pretax Margin
-5,163,499.50%

Debt

Sales & Book Value

Annual Sales
$320,000.00
Book Value
$3.09 per share

Miscellaneous

Free Float
22,548,000
Market Cap
$43.64 million
Optionable
Not Optionable
Beta
-0.89
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Benjamin J. Zeskind M.B.A. (Age 42)
    Ph.D., Co-Founder, President, CEO & Director
    Comp: $898.42k
  • Mr. Robert J. Carpenter M.B.A. (Age 78)
    M.S., Co-Founder & Chair Emeritus
    Comp: $83.17k
  • Dr. Brett M. Hall Ph.D. (Age 56)
    Chief Scientific Officer
    Comp: $867.92k
  • Ms. Mallory Morales CPA (Age 40)
    Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer
  • Ms. Paula George CPA
    Director of Accounting & Operations and Assistant Corporate Controller
  • Mr. Michael D. Bookman J.D. (Age 36)
    Chief Legal Officer & Secretary
  • Ms. Leah R. Neufeld (Age 52)
    Chief People Officer
  • Dr. Peter King Ph.D.
    Head of Discovery & VP
  • Dr. Praveen Nair Ph.D.
    Head of Translational Pharmacology & VP
  • Mr. Harold E. Brakewood (Age 59)
    Chief Business Officer

IMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Immuneering stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IMRX shares.
View IMRX analyst ratings
or view top-rated stocks.

What is Immuneering's stock price target for 2024?

8 equities research analysts have issued 1 year price objectives for Immuneering's stock. Their IMRX share price targets range from $3.00 to $25.00. On average, they anticipate the company's stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 800.0% from the stock's current price.
View analysts price targets for IMRX
or view top-rated stocks among Wall Street analysts.

How have IMRX shares performed in 2024?

Immuneering's stock was trading at $7.35 at the beginning of 2024. Since then, IMRX stock has decreased by 79.6% and is now trading at $1.50.
View the best growth stocks for 2024 here
.

Are investors shorting Immuneering?

Immuneering saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,880,000 shares, an increase of 10.3% from the March 15th total of 2,610,000 shares. Based on an average daily volume of 595,100 shares, the days-to-cover ratio is currently 4.8 days. Approximately 14.0% of the company's stock are short sold.
View Immuneering's Short Interest
.

When is Immuneering's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our IMRX earnings forecast
.

How were Immuneering's earnings last quarter?

Immuneering Co. (NASDAQ:IMRX) announced its quarterly earnings data on Friday, March, 1st. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.06.

When did Immuneering IPO?

Immuneering (IMRX) raised $105 million in an initial public offering on Friday, July 30th 2021. The company issued 7,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities served as the underwriters for the IPO.

How do I buy shares of Immuneering?

Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMRX) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners